Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients at High Risk of Acute Kidney Injury Undergoing Major Cardiovascular Surgery

NCT00683553 is registered in ClinicalTrials.gov with Quark Pharmaceuticals as lead sponsor.

NCT NCT00683553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00683553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blind, Dose Escalation Trial of the Safety and Pharmacokinetics of a Single Intravenous Injection of I5NP in Patients at High Risk of Acute Kidney Injury Undergoing Major Cardiovascular Surgery
Lead sponsor
Quark Pharmaceuticals
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2008
Completion date
September 30, 2010
Enrollment
3 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

acute kidney injury, acute renal failure